A detailed history of Csenge Advisory Group transactions in Amgen Inc stock. As of the latest transaction made, Csenge Advisory Group holds 7,077 shares of AMGN stock, worth $1.87 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
7,077
Previous 6,846 3.37%
Holding current value
$1.87 Million
Previous $2.14 Million 6.59%
% of portfolio
0.12%
Previous 0.12%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$309.38 - $337.38 $71,466 - $77,934
231 Added 3.37%
7,077 $2.28 Million
Q2 2024

Jul 10, 2024

BUY
$262.75 - $319.31 $25,486 - $30,973
97 Added 1.44%
6,846 $2.14 Million
Q1 2024

May 03, 2024

SELL
$268.87 - $324.56 $49,472 - $59,719
-184 Reduced 2.65%
6,749 $1.92 Million
Q4 2023

Feb 13, 2024

BUY
$255.7 - $288.46 $438,781 - $494,997
1,716 Added 32.89%
6,933 $2 Million
Q3 2023

Nov 01, 2023

BUY
$218.65 - $271.46 $525,853 - $652,861
2,405 Added 85.53%
5,217 $1.4 Million
Q2 2023

Jul 20, 2023

BUY
$214.27 - $253.37 $46,925 - $55,488
219 Added 8.45%
2,812 $624,000
Q1 2023

May 01, 2023

BUY
$225.79 - $275.2 $33,868 - $41,280
150 Added 6.14%
2,593 $626,000
Q4 2022

Feb 10, 2023

BUY
$229.03 - $291.01 $16,948 - $21,534
74 Added 3.12%
2,443 $641,000
Q3 2022

Oct 04, 2022

SELL
$224.46 - $253.15 $41,300 - $46,579
-184 Reduced 7.21%
2,369 $534,000
Q2 2022

Jul 27, 2022

BUY
$230.71 - $256.74 $79,825 - $88,832
346 Added 15.68%
2,553 $621,000
Q1 2022

May 09, 2022

SELL
$219.27 - $242.57 $47,581 - $52,637
-217 Reduced 8.95%
2,207 $534,000
Q4 2021

Feb 10, 2022

SELL
$198.88 - $227.6 $1,591 - $1,820
-8 Reduced 0.33%
2,424 $599,000
Q3 2021

Oct 20, 2021

BUY
$212.27 - $248.7 $1,698 - $1,989
8 Added 0.33%
2,432 $520,000
Q2 2021

Jul 21, 2021

BUY
$233.58 - $259.14 $91,563 - $101,582
392 Added 19.29%
2,424 $599,000
Q1 2021

Apr 28, 2021

SELL
$221.91 - $258.6 $163,769 - $190,846
-738 Reduced 26.64%
2,032 $506,000
Q4 2020

Jan 26, 2021

SELL
$216.38 - $257.67 $175,700 - $209,228
-812 Reduced 22.67%
2,770 $637,000
Q3 2020

Nov 09, 2020

SELL
$234.65 - $260.95 $17,129 - $19,049
-73 Reduced 2.0%
3,582 $905,000
Q2 2020

Jul 17, 2020

BUY
$197.81 - $242.74 $328,760 - $403,433
1,662 Added 83.39%
3,655 $862,000
Q1 2020

Apr 21, 2020

SELL
$182.24 - $241.7 $42,279 - $56,074
-232 Reduced 10.43%
1,993 $404,000
Q4 2019

Feb 05, 2020

SELL
$189.21 - $243.2 $5,487 - $7,052
-29 Reduced 1.29%
2,225 $536,000
Q3 2019

Nov 14, 2019

BUY
$174.11 - $208.62 $33,080 - $39,637
190 Added 9.21%
2,254 $436,000
Q2 2019

Jul 30, 2019

BUY
$166.7 - $195.41 $11,835 - $13,874
71 Added 3.56%
2,064 $380,000
Q1 2019

May 07, 2019

SELL
$180.87 - $203.88 $306,212 - $345,168
-1,693 Reduced 45.93%
1,993 $378,000
Q4 2018

Feb 07, 2019

BUY
$178.4 - $208.25 $43,708 - $51,021
245 Added 7.12%
3,686 $717,000
Q3 2018

Nov 19, 2018

SELL
$185.29 - $208.89 $223,459 - $251,921
-1,206 Reduced 25.95%
3,441 $655,000
Q2 2018

Aug 10, 2018

SELL
$166.05 - $186.51 $129,685 - $145,664
-781 Reduced 14.39%
4,647 $858,000
Q1 2018

May 10, 2018

BUY
$169.43 - $198.0 $81,326 - $95,040
480 Added 9.7%
5,428 $925,000
Q4 2017

Feb 15, 2018

SELL
$168.79 - $188.59 $119,840 - $133,898
-710 Reduced 12.55%
4,948 $860,000
Q3 2017

Oct 31, 2017

BUY
$167.29 - $191.0 $946,526 - $1.08 Million
5,658
5,658 $0

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Csenge Advisory Group Portfolio

Follow Csenge Advisory Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Csenge Advisory Group, based on Form 13F filings with the SEC.

News

Stay updated on Csenge Advisory Group with notifications on news.